Tris Pharma's ALLEVIATE-1 Trial Shows Promise for Cebranopadol in Pain Relief

Tris Pharma, Inc. (Tris), a biopharmaceutical company in the commercial stage, revealed encouraging topline findings from its ALLEVIATE-1 crucial Phase 3 clinical trial assessing cebranopadol, an experimental treatment, for addressing moderate-to...

Fermion and Simcere Pharma Partner on SSTR4 Pain Treatment Asset

Guangzhou Fermion Technology Co., Ltd., an AI-focused biotech firm in clinical development, and Simcere Pharmaceutical Group Limited, a pharmaceutical entity, have announced a collaboration to advance a clinical-stage pain treatment asset, FZ002...

PulseSight Therapeutics Submits CTA for Phase I Trial of PST-611

PulseSight Therapeutics SAS, a biotech firm focused on ophthalmology that creates groundbreaking non-viral vector therapies utilizing minimally-invasive delivery methods, has announced it has filed a Clinical Trial Authorization (CTA) with the...

Lyndra Therapeutics and Thermo Fisher Partner for Long-Acting Oral Therapies

Lyndra Therapeutics, a biopharmaceutical company in the clinical stage, has formed a strategic partnership with Thermo Fisher Scientific Inc., wherein Thermo Fisher will offer global clinical research and commercial manufacturing services to...

ProMIS Neurosciences Unveils Phase 1b Trial for Alzheimer's Candidate PMN310

ProMIS Neurosciences Inc., a biotechnology company at the clinical stage aimed at creating precise therapies for neurodegenerative diseases, announced the start of its phase 1b clinical trial (PRECISE-AD) assessing its primary therapeutic...

Crinetics Pharma Reports Positive Phase 2 study for Atumelnant in CAH

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical firm, announced encouraging topline findings from an open-label, phase 2 study on congenital adrenal hyperplasia (CAH) using investigational atumelnant, a new, once-daily oral...

CAGE Bio Launches Phase 2b Study for CGB-500 in Immuno-Dermatology

CAGE Bio, Inc., a biotechnology firm in clinical development focusing on novel treatments for prevalent immuno-dermatological conditions, announced the start of a phase 2b dose-ranging study for its CGB-500 product. This topical JAK inhibitor...

ModeX Therapeutics Commences Phase I EBV Vaccine Trial with Merck

ModeX Therapeutics Inc, announces that the first participant has been dosed in the phase I trial (NCT06655324) of an Epstein-Barr virus (EBV) vaccine candidate being developed alongside Merck, referred to as MSD outside the U.S. and Canada...

US FDA Proposes Tissue Biopsies in Clinical Trials

The US Food and Drug Administration (FDA) released a draft guidance in collaboration with the Office for Human Research Protections that, once finalized, will offer suggestions for incorporating tissue biopsies into clinical trials. The draft...

Adcentrx Commences Phase 1a/b Trial for Solid Tumor Therapy

Adcentrx Therapeutics (Adcentrx), a biotechnology company in clinical development focused on pioneering protein conjugates for cancer and other serious diseases, announced that the first patient has been dosed in the phase 1a/b trial of ADRX-0405...

© 2025 India Pharma Outlook. All Rights Reserved.

Safety Monitoring